impact factor
logo
 

Brief Paper

 

The relationship between metabolic syndrome severity and the risk of mortality in gout patients: a population-based study


1, 2, 3

 

  1. Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. schlesna@rutgers.edu
  2. Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA.
  3. Center for Liver Diseases and Liver Masses, Division of Gastroenterology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

CER15163
2022 Vol.40, N°3
PI 0631, PF 0633
Brief Paper

Free to view
(click on article PDF icon to read the article)

PMID: 35238754 [PubMed]

Received: 11/09/2021
Accepted : 17/12/2021
In Press: 01/02/2022
Published: 22/03/2022

Abstract

OBJECTIVES:
To examine Metabolic Syndrome (MetS) severity using a recently validated Metabolic Syndrome Severity Score (MetSSS) in order to explore the overall associations between MetSSS and the risk of mortality related to all-causes, heart disease, diabetes mellitus, and hypertension amongst American adults with gout.
METHODS:
Mortality-linked data for 12,101 adults aged 18 to 90 years who participated in the National Health and Nutrition Examination Survey III by gout status was analysed. All 5 metabolic features were used to calculate gender-race/ethnicity-specific MetSSS Z-scores in gout patients. The calculated Z-scores are a continuous representation of all MetS conditions while accounting for gender-race/ethnicity disparities.
RESULTS:
A total of 3,381 deaths were observed, of which 215 had gout. The prevalence amongst adults was 2.59%. Moderate to high MetS severity was significantly prevalent amongst gout patients (47.33% vs. 21.16 % no gout; p-value <0.0001). The mean MetSSS Zscore for gout patients was significantly higher than those without gout (0.71 vs. -0.04 no gout; p-value <0.0001). A one-unit increase in MetSSS score was associated with significant increases in the risk of all-cause mortality, heart disease, diabetes- and hypertension-related mortalities.
CONCLUSIONS:
Moderate to high MetSSS is significantly prevalent amongst gout patients. A one-unit increase in MetSSS score was associated with significant increases in the risk of all-cause mortality, heart disease, diabetes- and hypertension-related mortalities. MetS is a clinically accessible tool for predicting mortality risks in gout patients with MetS.

DOI: https://doi.org/10.55563/clinexprheumatol/2rn9fv

Rheumatology Article